Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI problems due to the inhibition in the synthesis of gastroprotective brokers including PGE2 and various prostaglandins. This inhibition causes decreased mucin manufacturing by gastric epithelial cells, considerably less bicarbonate secretion, and fewer epithelial cell turnover, amid other steps. This https://annew579cgh6.wikimidpoint.com/user